This case report highlights the risk of major, potentially irreversible intra-abdominal hemorrhage associated with rivaroxaban use.
Answers are grounded in this paper and cite their sources.
Warrants perioperative bleeding caution with rivaroxaban; single case leaves management questions open.
We discuss the first ever case of rivaroxaban causing major intra-abdominal hemorrhage found in a patient during emergency hernioplasty. The source of bleeding was not identified either intra- or postoperatively. This is on a background of treatment for deep vein thrombosis (DVT) with rivaroxaban, a complication that resulted from a total knee arthroplasty performed four weeks prior. Rivaroxaban is a new generation of anticoagulants that directly inhibits factor Xa and is used for DVT treatment in major orthopaedic surgery. Here we discuss the major side effects of rivaroxaban, namely, the increased risk of major bleeding as well as the irreversibility of this anticoagulant, should such bleeding occur. We advise caution in the use of rivaroxaban even in patients that are at low risk of bleeding given the discovery of hemorrhage as presented in this case.
No takes yet. Share an insight, caveat, or question.
Chow et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: